Evidence Ledger: What Claims Actually Have Support
The research that we saw on PubMed blew our minds
It is classified as a research compound and is available through compounding pharmacies under certain regulatory frameworks
That means you cannot legitimately place 10.8% for cagrilintide next to 24.2% for retatrutide and declare a winner, because those numbers come from different trials, different populations, different durations (26 vs 48 weeks), different doses, and critically a monotherapy figure for one versus a monotherapy figure for the other, while cagrilintides strongest data are actually as a combination
As the founder of Seeds Scientific Research & Performance (SSRP), he leads the world's top institution dedicated to advancing the understanding and applications of cellular and peptide therapy
*Correspondence: Manxin Fang [email protected] This article was submitted to Veterinary Pharmacology and Toxicology, a section of the journal Frontiers in Veterinary Science Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
